# The cutaneous beta human papillomavirus type 8 E6 protein induces CCL2 through the CEBPα/miR-203/p63 pathway to support an inflammatory microenvironment in epidermodysplasia verruciformis skin lesions

**Authors:** Luca Vella, Anna Sternjakob, Stefan Lohse, Alina Fingerle, Tanya Sperling, Claudia Wickenhauser, Michael Stöckle, Thomas Vogt, Klaus Roemer, Monika Ołdak, Sigrun Smola

PMC · DOI: 10.3389/fcimb.2024.1336492 · 2024-03-06

## TL;DR

This study shows how the HPV8 E6 protein causes inflammation in skin lesions of a rare disease by altering immune signals and promoting a cancer-friendly environment.

## Contribution

The study identifies a novel pathway involving CCL2 induction via CEBPα/miR-203/p63 by HPV8 E6, linking inflammation to potential carcinogenesis in EV.

## Key findings

- HPV8 E6 strongly induces CCL2, a monocyte-attracting chemokine, more effectively than TNF-α.
- HPV8 E6 modulates the CEBPα/miR-203/p63 pathway to promote an inflammatory microenvironment.
- Macrophages are prevalent in EV lesions, and CCL2 is co-expressed with p63 in infected skin.

## Abstract

Human papillomavirus type 8 (HPV8), a cutaneous genus beta HPV type, has co-carcinogenic potential at sun-exposed sites in patients suffering from the inherited skin disease epidermodysplasia verruciformis (EV). We had previously shown that Langerhans cells responsible for epithelial immunosurveillance were strongly reduced at infected sites and that the HPV8 E7 protein interferes with the CCAAT/enhancer-binding protein (C/EBP)β to suppress the Langerhans cell chemokine CCL20. At the same time, however, we observed that EV lesions are heavily infiltrated with inflammatory immune cells, which is similar to the situation in HPV8 E6 transgenic mice. To identify critical inflammatory factors, we used a broad multiplex approach and found that the monocyte attracting chemokine CCL2 was significantly and strongly induced by HPV8 E6 but not E7-expressing HaCaT cells, which were used as a model for UV-damaged skin keratinocytes. Conditioned media from HPV8 E6-expressing keratinocytes enhanced CCL2-receptor (CCR2)-dependent monocyte recruitment in vitro, and macrophages predominated in the stroma but were also detected in the epidermal compartment of EV lesions in vivo. CCL2 induction by HPV8 E6 was even stronger than stimulation with the proinflammatory cytokine TNF-α, and both HPV8 E6 and TNF-α resulted in substantial suppression of the transcription factor C/EBPα. Using RNAi-mediated knockdown and overexpression approaches, we demonstrated a mechanistic role of the recently identified C/EBPα/miR-203/p63 pathway for HPV8 E6-mediated CCL2 induction at protein and transcriptional levels. Epithelial co-expression of p63 and CCL2 was confirmed in HPV8 E6-expressing organotypic air–liquid interface cultures and in lesional EV epidermis in vivo. In summary, our data demonstrate that HPV8 oncoproteins actively deregulate epidermal immune homeostasis through modulation of C/EBP factor-dependent pathways. While HPV8 E7 suppresses immunosurveillance required for viral persistence, the present study provides evidence that E6 involves the stemness-promoting factor p63 to support an inflammatory microenvironment that may fuel carcinogenesis in EV lesions.

## Linked entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051], CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050], MIR203A (microRNA 203a) [NCBI Gene 406986], RPE65 (retinoid isomerohydrolase RPE65) [NCBI Gene 6121]
- **Proteins:** CCL2 (C-C motif chemokine ligand 2), CCR2 (C-C motif chemokine receptor 2), CEBPB (CCAAT enhancer binding protein beta), CEBPA (CCAAT enhancer binding protein alpha), RPE65 (retinoid isomerohydrolase RPE65)
- **Diseases:** epidermodysplasia verruciformis (MONDO:0009176)

## Full-text entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, MIR203A (microRNA 203a) [NCBI Gene 406986] {aka MIR203, MIRN203, hsa-mir-203a, miR-203, miRNA203, mir-203a}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** EV (MESH:D004819), inflammatory (MESH:D007249), carcinogenesis (MESH:D063646), inherited skin disease (MESH:D030342)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], human papillomavirus 8 (serotype) [taxon 10579]
- **Cell lines:** HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10953690/full.md

---
Source: https://tomesphere.com/paper/PMC10953690